1. Home
  2. AKBA vs LMNR Comparison

AKBA vs LMNR Comparison

Compare AKBA & LMNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.23

Market Cap

251.0M

Sector

Health Care

ML Signal

HOLD

Logo Limoneira Co

LMNR

Limoneira Co

HOLD

Current Price

$13.06

Market Cap

235.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
LMNR
Founded
2007
1893
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Farming/Seeds/Milling
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
251.0M
235.0M
IPO Year
2014
2005

Fundamental Metrics

Financial Performance
Metric
AKBA
LMNR
Price
$1.23
$13.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$4.67
$20.00
AVG Volume (30 Days)
4.1M
74.5K
Earning Date
05-07-2026
06-08-2026
Dividend Yield
N/A
2.37%
EPS Growth
93.94
N/A
EPS
N/A
N/A
Revenue
N/A
$159,723,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$13.95
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$11.67
52 Week High
$3.81
$16.62

Technical Indicators

Market Signals
Indicator
AKBA
LMNR
Relative Strength Index (RSI) 46.66 46.20
Support Level $1.16 $12.54
Resistance Level $1.52 $13.65
Average True Range (ATR) 0.07 0.39
MACD -0.02 -0.07
Stochastic Oscillator 7.59 7.51

Price Performance

Historical Comparison
AKBA
LMNR

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About LMNR Limoneira Co

Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.

Share on Social Networks: